Literature DB >> 17033266

Acromegaly and end-stage renal disease: a diagnostic challenge.

K Müssig1, B Gallwitz, M B Ranke, M Horger, H U Häring, H J Quabbe.   

Abstract

Chronic renal failure is associated with an impairment of the GH/IGF-I axis. We report the diagnostic challenges in a 72-yr-old female suffering from end-stage renal disease and presenting with clinical findings suggestive of acromegaly. GH was not suppressed during an oral glucose tolerance test, but rose paradoxically. However, serum IGF-I levels were within the normal range. IGF-binding proteins (IGFBP)-2 and -3 were markedly elevated and GH-binding protein (GHBP) was diminished. Clinical findings suspicious of acromegaly could be ascribed to pre-existing characteristics and consequences of end-stage renal disease. This suggested that the disturbances of the GH/IGF-I axis in our patient were due to chronic renal disease, rather than acromegaly. In the work-up for acromegaly, clinicians should be alerted to GH resistance in chronic renal failure.

Entities:  

Mesh:

Year:  2006        PMID: 17033266     DOI: 10.1007/BF03344187

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  32 in total

1.  Serum-growth hormone and glucose intolerance in renal failure.

Authors:  A D Wright; C Lowy; T R Fraser; I M Spitz; A H Rubenstein; I Bersohn
Journal:  Lancet       Date:  1968-10-12       Impact factor: 79.321

Review 2.  The growth hormone and insulin-like growth factor axis: its manipulation for the benefit of growth disorders in renal failure.

Authors:  Vincent Roelfsema; Ross G Clark
Journal:  J Am Soc Nephrol       Date:  2001-06       Impact factor: 10.121

Review 3.  Derangements of the somatotropic hormone axis in chronic renal failure.

Authors:  B Tönshoff; W F Blum; O Mehls
Journal:  Kidney Int Suppl       Date:  1997-03       Impact factor: 10.545

4.  Changes in serum insulin-like growth factor binding protein-2, -3, and -6 levels in patients with chronic renal failure following renal transplantation.

Authors:  I Fukuda; N Hizuka; Y Okubo; K Takano; K Asakawa-Yasumoto; K Shizume; H Demura; N Kimata; N Ishikawa; H Toma
Journal:  Growth Horm IGF Res       Date:  1998-12       Impact factor: 2.372

5.  Paradoxical elevations in serum IGF-II and IGF binding protein-2 in acromegaly: insights into the regulation of these peptides.

Authors:  A G Renehan; A A Toogood; W D Ryder; J Jones; C S Potten; S T O'Dwyer; S M Shalet
Journal:  Clin Endocrinol (Oxf)       Date:  2001-10       Impact factor: 3.478

Review 6.  Clinical studies of IGFBP-2 by radioimmunoassay.

Authors:  W F Blum; N Horn; J Kratzsch; J O Jørgensen; A Juul; D Teale; K Mohnike; M B Ranke
Journal:  Growth Regul       Date:  1993-03

7.  Urinary insulin-like growth factors (IGF) and IGF-binding proteins in normal subjects, growth hormone deficiency, and renal disease.

Authors:  S E Gargosky; T Hasegawa; P Tapanainen; M MacGillivray; Y Hasegawa; R G Rosenfeld
Journal:  J Clin Endocrinol Metab       Date:  1993-06       Impact factor: 5.958

8.  Chronic uremia attenuates growth hormone-induced signal transduction in skeletal muscle.

Authors:  Di Fei Sun; Zhilan Zheng; Padmaja Tummala; Jun Oh; Franz Schaefer; Ralph Rabkin
Journal:  J Am Soc Nephrol       Date:  2004-10       Impact factor: 10.121

9.  Evaluation of disease status with sensitive measures of growth hormone secretion in 60 postoperative patients with acromegaly.

Authors:  P U Freda; K D Post; J S Powell; S L Wardlaw
Journal:  J Clin Endocrinol Metab       Date:  1998-11       Impact factor: 5.958

10.  Radioimmunological determination of insulinlike growth factors I and II in normal subjects and in patients with growth disorders and extrapancreatic tumor hypoglycemia.

Authors:  J Zapf; H Walter; E R Froesch
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

View more
  1 in total

Review 1.  Dynamic tests for the diagnosis and assessment of treatment efficacy in acromegaly.

Authors:  Laure Cazabat; Jean-Claude Souberbielle; Philippe Chanson
Journal:  Pituitary       Date:  2008       Impact factor: 4.107

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.